Biotech company Immutep Ltd (ASX:IMM) has received a R&D Tax Incentive of around A$3.6 million from the French Government to boost development of two current product candidates. The incentive – worth €2,194,918 – was provided under the government’s Crédit d’Impôt Recherche scheme (CIR) – for which Immutep is eligible due to activities carried out at its laboratory in France. Under the scheme, companies can be reimbursed 30% of their eligible expenditure on research and development activities. In this case, Immutep will be plugging it into global clinical development of candidates eftilagimod a…